Skip to main content

Surgical oncology · research overview

Emerging Research in Surgical Oncology

Start with your cancer type. Each record opens in plain language; clinician detail is one click away. For information only — not a treatment recommendation.

Browse by cancer type

Start here if you are asking “is there anything new in my cancer?”

Recent updates

Featured

Filter all

Editorial picks — a few cards highlighted each month.

Pioneering clinical study — approach supported by longer-term resultsPhase IINCT04165772

Primary analysis

Can rectal cancer be treated without surgery in some patients?

Rectum

NEJM 2025: complete clinical response in 49/49 who completed treatment (complete clinical response ≠ cure)

Pioneering phase II; NEJM 2025 complete clinical response in 49/49 who completed treatment. Single-arm; AZUR-1 is a separate confirmatory trial.

Newly reported results · Registry checked: 2026-10-29

Phase III · Positive results published · US-approvedPhase IIINCT06625320

Primary analysis · FDA approval — 26 August 2026 (US). Indication: metastatic pancreatic adenocarcinoma in adults after ≥1 prior systemic therapy or who are not candidates for multiagent systemic therapy. Label is not limited to RAS mutation. Türkiye license/SGK are separate.

Does daraxonrasib prolong survival in previously treated metastatic pancreatic cancer?

Pancreas

Median overall survival 13.2 vs 6.7 mo (overall population) · US approval; Türkiye separate

Positive phase III overall survival/progression-free survival (NEJM); US-approved. Access in Türkiye separate. RAS G12 primary; overall population and label read separately.

Practice-entering research · Registry checked: 2026-10-29

Phase III · Positive results published · US-approvedPhase IIINCT02912559

Primary analysis · FDA regular approval — 8 October 2026 (US). Atezolizumab (± subcutaneous hyaluronidase formulation) + fluoropyrimidine/oxaliplatin; adjuvant stage III dMMR colon. Türkiye license/SGK separate.

ATOMIC — Adding immunotherapy to chemotherapy after surgery in colon cancer

Colon

Primary card: Colon Landmark Atlas · Emerging is a bridge

Phase III disease-free survival benefit (NEJM); US-approved. overall survival not settled. Access in Türkiye separate. Primary card: Colon Landmark Atlas.

Practice-entering research · Registry checked: 2026-11-03

Three reading layers

Phase and publication type stay as small badges; the main axis answers the patient’s question.

How these treatments work

Technology areas such as mRNA vaccines, targeted protein degradation, and next-generation antibody–drug conjugates. Not a single trial — linked study cards sit underneath.

Research areaEmerging treatment technologiesPriority: very high

Personalized mRNA cancer vaccines

Melanoma · Pancreas · Multiple / solid tumors

Research area: personalized mRNA vaccines. KEYNOTE-942, V940 phase III, and pancreas vaccine cards are listed separately underneath.

Evidence level: Randomized phase IIb results in melanoma plus phase III confirmation trials; early clinical in pancreas.

Not a single trial · 3 linked records

Research areaEmerging treatment technologiesPriority: very high

PROTACs — targeted protein degradation

Pancreas · Multiple / solid tumors

Research area: protein degradation. Setidegrasib (KRAS G12D) clinical card underneath; separate from classic inhibitor cards.

Evidence level: 2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.

Not a single trial · 1 linked records

Research areaEmerging treatment technologiesPriority: very high

Bispecific antibody–drug conjugates (BsADCs)

Gastric / esophageal · Biliary tract · Multiple / solid tumors

Research area: BsADCs. BL-B01D1 esophagus/biliary phase III cards underneath; zanidatamab is not an ADC.

Evidence level: Some molecules in phase III / regional programs; izalontamab brengitecan (BL-B01D1) as an example. Not all BsADCs are equivalent.

Not a single trial · 2 linked records

Research areaEmerging treatment technologiesPriority: high

Armored CAR-T — solid tumors

Multiple / solid tumors

Research area: armored CAR-T. Early-phase ARMADA example underneath; do not conflate with hematologic CAR-T.

Evidence level: Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.

Not a single trial · 1 linked records

Relationship to the Landmark Atlas

When a study changes the standard of cancer care, its primary home is the Landmark Atlas. This page summarizes emerging and newly reported research; a positive result is not automatically a new standard.